WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics (NYSE MKT: CVRS) today announced the formation of a joint robotic-assisted percutaneous coronary intervention (PCI) research and clinical program. The program utilizes the company’s CorPath® System, the first and only FDA-cleared medical device to provide robotic-assisted precision to coronary PCI procedures while protecting hospital employees from occupational radiation exposure and orthopedic stress and strain.
Mayo Clinic physicians are using robotic technology to help patients with coronary artery disease (CAD) and initiating collaborative research projects to enhance the use of robotic technology to improve patient care as well as provider safety. The research at Mayo Clinic will be led by Gurpreet S. Sandhu, M.D., Ph.D, a Mayo Clinic cardiologist, and Director, Dr. Earl Wood Cardiac Catheterization Laboratory.
In April of 2015, the Journal of the American College of Cardiology published research highlighting the occupational health hazards of working in interventional laboratories based on research conducted by investigators at Mayo Clinic. Amongst the concerns were potential musculoskeletal and back injuries to providers from wearing lead-lined protective garments in hospital catheterization laboratories.
"The occupational hazards in this field can be devastating to people. Vascular robotics provide the biggest change to cath lab procedures in 30 years and is transforming the environment by reducing radiation exposure and spinal stresses to physicians and providing robotic precision of interventional device manipulation," said David Handler, President and CEO of Corindus. "Collaboration between Corindus and leading physicians and scientists is an important and exciting step toward accelerating the progress currently being made by robotic technology in the cardiology field."
Today, interventional procedures performed in hospital cath labs are a leading source of radiation exposure for medical personnel and has been linked to the development of cataracts, cancer, and brain and thyroid diseases. The CorPath System allows interventional cardiologists to perform procedures in a protected cockpit just a few feet away from the patient bed side. Seated in this radiation-protected cockpit, the physician uses intuitive digital controls to robotically advance guidewires, angioplasty balloons and stents through coronary arteries.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to PCI procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus’ financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward Looking Statements” section of Corindus' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus’ website at http://www.corindus.com/about-corindus/investor-relations. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.